Bayesian sample size for exploratory clinical trials incorporating historical data

被引:37
|
作者
Whitehead, John [1 ]
Valdes-Marquez, Elsa [2 ]
Johnson, Patrick [3 ]
Graham, Gordon [3 ]
机构
[1] Univ Lancaster, Fylde Coll, Dept Math & Stat, MPS Res Unit, Lancaster LA1 4YE, England
[2] Univ Reading, Sect Quantitat Biol & Appl Stat, Reading, Berks, England
[3] Pfizer Global Res & Dev, Sandwich, Kent, England
关键词
Bayesian methods; clinical trial; phase II trial; proof-of-concept study; sample size; score statistic;
D O I
10.1002/sim.3140
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This paper presents a simple Bayesian approach to sample size determination in clinical trials. It is required that the trial should be large enough to ensure that the data collected will provide convincing evidence either that an experimental treatment is better than a control or that it fails to improve upon control by some clinically relevant difference. The method resembles standard frequentist formulations of the problem, and indeed in certain circumstances involving 'non-informative' prior information it leads to identical answers. In particular, unlike many Bayesian approaches to sample size determination, use is made of an alternative hypothesis that an experimental treatment is better than a control treatment by some specified magnitude. The approach is introduced in the context of testing whether a single stream of binary observations are consistent with a given success rate p(0). Next the case of comparing two independent streams of normally distributed responses is considered, first under the assumption that their common variance is known and then for unknown variance. Finally, the more general situation in which a large sample is to be collected and analysed according to the asymptotic properties of the score statistic is explored. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:2307 / 2327
页数:21
相关论文
共 50 条
  • [31] Sample size reestimation in clinical trials
    Shun, ZM
    [J]. DRUG INFORMATION JOURNAL, 2001, 35 (04): : 1409 - 1422
  • [32] On the sample size of clinical trials - revisited
    Papageorgiou, Spyridon N.
    [J]. JOURNAL OF ORTHODONTICS, 2018, 45 (04) : 296 - 298
  • [33] Sample size calculation based on efficient unconditional tests for clinical trials with historical controls
    Shan, Guogen
    Moonie, Sheniz
    Shen, Jay
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (02) : 240 - 249
  • [34] Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count data
    Igeta, Masataka
    Takahashi, Kunihiko
    Matsui, Shigeyuki
    [J]. BIOMETRICS, 2018, 74 (04) : 1459 - 1467
  • [35] Calculating sample size in trials using historical controls
    Zhang, Song
    Cao, Jing
    Ahn, Chul
    [J]. CLINICAL TRIALS, 2010, 7 (04) : 343 - 353
  • [36] INCORPORATING HISTORICAL CONTROL DATA IN PLANNING PHASE-II CLINICAL-TRIALS
    THALL, PF
    SIMON, R
    [J]. STATISTICS IN MEDICINE, 1990, 9 (03) : 215 - 228
  • [37] Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials
    Daimon, Takashi
    [J]. CONTEMPORARY CLINICAL TRIALS, 2008, 29 (04) : 507 - 516
  • [38] Bayesian sample size calculations in phase II clinical trials using informative conjugate priors
    Mayo, MS
    Gajewski, BJ
    [J]. CONTROLLED CLINICAL TRIALS, 2004, 25 (02): : 157 - 167
  • [39] Bayesian Model for Real Time Minimization of Sample Size in Phase IV Clinical Trials in Transplantation
    Tremblay, S.
    Ejaz, N.
    Shields, A.
    Alloway, R.
    Cuffy, M.
    Abu Jawdeh, B.
    Woodle, E.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 550 - 551
  • [40] Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors
    Gajewski, Byron J.
    Mayo, Matthew S.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (15) : 2554 - 2566